Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab? No — single-arm phase 2 study of 贝莫苏拜单抗 injection plus anlotinib in advanced or unresectable alveolar soft part sarcoma
CTR20260890Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in alveolar soft part sarcoma (ASPS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2026; status: active.
02
Drugs
anlotinib
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on CTR20260890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260890.